RemeGen Executive and Leadership Team

Jianmin Fang, the Chief Executive Officer at RemeGen, directs the overarching strategic vision for biopharmaceutical development. Fang architects the long-term research roadmap, focusing specifically on the advancement of Telitacicept and other fusion protein platforms. By aligning scientific discovery with clinical milestones, the Chief Executive Officer ensures the company maintains a competitive edge in the autoimmune disease sector. Jianmin Fang manages high-level partnerships with global research institutions to accelerate drug pipeline maturation. This leadership role involves constant evaluation of therapeutic efficacy and safety profiles to meet international regulatory standards. Through rigorous oversight of the R&D division, the Chief Executive Officer drives the transition of experimental compounds into viable commercial products. Fang maintains a focus on sustainable growth, ensuring that the company remains at the forefront of medical innovation while addressing critical unmet needs in oncology and immunology across diverse patient populations.

Jian Lin, the Executive Director & Chief Executive Officer at RemeGen, oversees corporate governance and the execution of enterprise-wide business objectives. Lin coordinates the integration of internal departments to support the commercialization of Disitamab Vedotin. As the Executive Director & Chief Executive Officer, Lin manages the alignment of board-level directives with daily operational activities. This position requires constant interaction with stakeholders to secure the resources necessary for large-scale clinical trials. Jian Lin drives the expansion of the company footprint, focusing on market penetration strategies that leverage the unique properties of antibody-drug conjugates. By optimizing organizational structure, Lin ensures that the company remains agile in a rapidly evolving pharmaceutical landscape. The Executive Director & Chief Executive Officer monitors financial health and risk management protocols to protect shareholder interests. Through strategic planning, Lin fosters a culture of excellence that supports the delivery of high-quality therapeutic solutions to patients worldwide.

Shaojing Tong, the Chief Financial Officer at RemeGen, manages the fiscal health and capital allocation strategies essential for sustained biopharmaceutical research. Tong oversees the budgeting process for extensive clinical development programs, ensuring that resources support the most promising drug candidates. As the Chief Financial Officer, Tong directs investor relations and financial reporting, maintaining transparency with global capital markets. This role involves analyzing market trends to optimize funding for the company pipeline, particularly regarding the production of complex fusion proteins. Shaojing Tong evaluates the financial viability of international expansion efforts, balancing growth initiatives with prudent cost management. By implementing robust financial controls, the Chief Financial Officer supports the long-term stability of the organization. Tong collaborates with other executive leaders to align fiscal planning with the broader mission of delivering innovative cancer treatments. Through precise financial modeling, the Chief Financial Officer secures the necessary capital to fuel continuous scientific advancement and operational success.

Kaisheng Huang, the Chief Operating Officer & Chief Quality Officer at RemeGen, manages the end-to-end manufacturing processes and rigorous quality assurance standards for all pharmaceutical products. Huang architects the supply chain infrastructure required to support the global distribution of complex fusion proteins. As the Chief Operating Officer & Chief Quality Officer, Huang ensures that every stage of production adheres to international regulatory requirements and internal safety protocols. This role involves overseeing facility operations and optimizing manufacturing efficiency to meet the growing demand for cancer treatments. Kaisheng Huang directs the implementation of advanced quality control systems, minimizing risks and ensuring product consistency. By coordinating with the R&D and clinical teams, the Chief Operating Officer & Chief Quality Officer facilitates the seamless transition of drugs from development to commercial-scale manufacturing. Huang maintains a focus on operational excellence, driving continuous improvement initiatives that enhance the overall reliability of the company production capabilities and therapeutic output.

Michael Shi, the Chief Marketing Officer at RemeGen, leads the commercialization strategy for the company portfolio of autoimmune and oncology therapies. Shi architects the brand positioning for Disitamab Vedotin, ensuring that healthcare providers understand the clinical benefits of these advanced antibody-drug conjugates. As the Chief Marketing Officer, Shi directs the development of educational programs and market access initiatives across major global regions. This role involves analyzing competitive landscapes to identify opportunities for product differentiation in the pharmaceutical sector. Michael Shi manages the communication of clinical trial results to medical communities, fostering trust and adoption of new therapeutic standards. By coordinating with sales and medical affairs teams, the Chief Marketing Officer ensures consistent messaging regarding product efficacy and safety. Shi drives the expansion of the company market presence, focusing on building strong relationships with key opinion leaders. Through strategic marketing campaigns, the Chief Marketing Officer accelerates the delivery of life-saving treatments to patients.